ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

AFX Carl Zeiss Meditec AG

61.25
-0.25 (-0.41%)
24 Jul 2024 - Closed
Realtime Data
Share Name Share Symbol Market Type
Carl Zeiss Meditec AG TG:AFX Tradegate Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.25 -0.41% 61.25 61.00 61.50 61.60 60.55 61.60 10,647 22:50:02

Afrox Concludes Largest Empowerment Transaction Outside of the Mining Sector

17/11/2003 1:43pm

PR Newswire (US)


Carl Zeiss Meditec (TG:AFX)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Carl Zeiss Meditec Charts.
Afrox Concludes Largest Empowerment Transaction Outside of the Mining Sector JOHANNESBURG, November 17 /PRNewswire/ -- African Oxygen Limited ("Afrox") (JSE: AFX) today announced that its subsidiary company, Afrox Healthcare Limited ("AHealth"), will become the first BEE-owned and controlled private hospital group in South Africa. This follows Afrox's decision to sell its 69% stake in AHealth to a consortium of BEE investors, Business Venture Investments Limited ("Bidco"), for R3.1 billion. Bidco is to be approximately 75% owned by a BEE consortium, with the balance to be held by Medi-Clinic Corporation Limited ("Medi-Clinic"). The BEE consortium is to be led by Brimstone Investment Corporation Limited ("Brimstone") and Mvelaphanda Strategic Investments (Proprietary) Limited ("Mvelaphanda"), supported by nationally and regionally based doctor and empowerment groupings ensuring broad based empowerment. Commenting on this landmark deal, Afrox CEO Rick Hogben said: "We are very proud to be a part of this ground breaking deal. We have realised the benefits of our investment in Healthcare and although they will continue to provide sound growth, the bulk of the industry consolidation and acquistional growth has been achieved. The Afrox Board felt strongly that a deal which provided AHealth with a BEE partner was vital if it was to remain competitive and be positioned to pursue new investment in the healthcare sector, both locally and globally. "We believe that the business has reached the requisite scale and level of success and sophistication such that operating as an autonomous, empowered entity will better enable it to pursue its own growth initiatives, without restriction." The cash sale consideration is R13.85 per AHealth share, escalated at an effective rate of 5.60% per annum from 1 October 2003 to the date of the scheme being implemented. For example, if the scheme operative date is 30 April 2004, the offer consideration, including the escalation, is R14.30. In addition AHealth shareholders on the share register on 23 January 2004, will be entitled to retain the dividend of R0.40 per share for the year ended 30 September 2003. AHealth will be sold as a going concern and all managers and staff will be kept intact through the transaction. Commenting on joining forces with Bidco, Mike Flemming, MD of AHealth said: "I welcome the South African ownership of AHealth and it being solely focused on healthcare delivery. This ensures an alignment of the Bidco's strategy with that of AHealth. "I am excited by the calibre of the empowerment component of Bidco as it is a critical prerequisite for business success in South Africa." Over the past two years, Afrox has focused on developing new markets, extending its global customer base and added to its product and service offerings to existing and new customers. It has optimised its human capital, technology, and production facilities to increase its productivity and global competitiveness, improving its brand awareness and marketing focus whilst becoming customer and service centred. "Few synergies exist between the industrial and Healthcare businesses - as each division has grown, so dysynergies have become evident in areas such as HR, IM and Finance. With both businesses generating good cash returns, we decided that a separation would ensure continued growth," Hogben added. "The sale of Afrox Healthcare represents a major step in delivering on the Group's primary objective of maximising the potential of its Industrial businesses. We will focus on new innovative ways of growing market share and creating further operational improvements. We will also consider earnings enhancing acquisitions, including additional expansion into Africa," Hogben concluded. Mr. Chris Fieldgate, Investor Relations, Tel: +27 11 490 0430 e-mail: chris.fieldgate@afrox.boc.com Linda Burrows, +27 11 490 0554

Copyright

1 Year Carl Zeiss Meditec Chart

1 Year Carl Zeiss Meditec Chart

1 Month Carl Zeiss Meditec Chart

1 Month Carl Zeiss Meditec Chart

Your Recent History

Delayed Upgrade Clock